EGFR and non-small cell lung carcinoma: Interestingly, a similar result for worse survival in the highest plasma exposure group (Q4) was observed in a cohort of EGFR-mutant NSCLC patients treated with erlotinib, suggesting a class effect for this PK/PD relationship.